DE2530372A1 - Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts. - Google Patents

Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts.

Info

Publication number
DE2530372A1
DE2530372A1 DE19752530372 DE2530372A DE2530372A1 DE 2530372 A1 DE2530372 A1 DE 2530372A1 DE 19752530372 DE19752530372 DE 19752530372 DE 2530372 A DE2530372 A DE 2530372A DE 2530372 A1 DE2530372 A1 DE 2530372A1
Authority
DE
Germany
Prior art keywords
acid
fumaric acid
salts
parts
compsns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19752530372
Other languages
German (de)
Inventor
Walter Dr Schweckendiek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19752530372 priority Critical patent/DE2530372A1/en
Publication of DE2530372A1 publication Critical patent/DE2530372A1/en
Priority to DE19772703964 priority patent/DE2703964A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A palatable, oral compsn for treatment of psoriasis, which is easy to measure out, consists of >=1 fumaric acid cpd. (I) diluted with the acid alkali salts of tartaric citric and ascorbic acid, and with MgSO4 and sugar, and is administered dissolved in water. (I) is fumaric acid itself; its neutral or acid salts:di- or mono-esters or their salts including Mn salts. Also new are topical (I)-based compsns. applied together with the acid salts of tartaric and citric acids and opt. with Vitamin A acid. The compsns. quickly normalise the metabolic status in cases of psoriasis and also improve circulatory disorders and senile diabetes, and normalise cholesterol levels. The solns. have an acceptable baste, are readily accepted by children and alleviate gastric and intestinal disorders from which many psoriasis patients suffer. A compsns. for adding to bathing water comprises (wt. pts.) fumaric acid 100; dimethyl fumarate 100; tartaric acid 100; K or NaHCO3 150; citric acid 50. 2-5 Teaspoons are added to the bath.

Description

Pharmazeutische Zubereitungen zur Behandlung von PSORIASIS Beschreibung Seit 1959 ist bekannt, daß man Psoriasis mit Fumarsäure und ihren Verbindungen erfolgreich behandeln kann(1). Die Verbindungen werden intern und extern appliziert1)2)3)4)5)6)7).Pharmaceutical preparations for the treatment of PSORIASIS Description Since 1959 it has been known that psoriasis can be successfully treated with fumaric acid and its compounds can treat (1). The connections are applied internally and externally1) 2) 3) 4) 5) 6) 7).

Fast jeder Patient jedoch bedarf speziell bei Psoriasis einer individuellen Behandlung. Der Dosierung kommt dabei größte Bedeutung zu. So wurden jetzt Zubereitungen entwickelt, die den geforderten Ansprüchen hervorragend genügen. Zu diesem Zweck verdünnt man z. B. die hochaktiven Fumarsäurederivate vorteilhaft mit den sauren Salzen der Wein-, Zitronen- und Ascorbinsäure sowie mit Magnesium- oder Natriumsulfat. Die Dosierung ist dann sehr einfach. Man verfährt dabei in der Weise, daß man z. B. einen Teil der in "Medizin heute" (19) 1970, S. 10 publizierten Rezeptur M mit 20, 30 oder 50 Teilen eines Pulvers, bestehend aus: 192 Tl. Weinsäure 30 Tl. Zitronensäure 6 Tl. Ascorbinsäure 220 Tl. Magnesiumsulfat oder Natriumsulfat (wasserfrei) Pulver VD 210 Tl. Natriumbikarbonat 342 Tl. Zucker 1000 Tl. Almost every patient, however, requires individual treatment, especially for psoriasis. The dosage is of the utmost importance. Preparations have now been developed that perfectly meet the requirements. For this purpose one dilutes z. B. the highly active fumaric acid derivatives advantageously with the acidic salts of tartaric, citric and ascorbic acid and with magnesium or sodium sulfate. The dosage is then very simple. One proceeds in such a way that one z. B. part of the formulation M published in "Medizin heute" (19) 1970, p. 10, with 20, 30 or 50 parts of a powder, consisting of: 192 tsp. Tartaric acid 30 teaspoons of citric acid 6 teaspoons of ascorbic acid 220 tsp. Magnesium sulfate or sodium sulfate (anhydrous) powder VD 210 tsp. Sodium bicarbonate 342 teaspoons of sugar 1000 Tl.

vermischt.mixed.

Der Einfachheit halber sei das Verdünnungspulver mit VD bezeichnet. Wählt man ein Verhältnis von Rezeptur M (4) : Pulver VD = 1 : 35, so enthält ein Teelöffel etwa 5 g der Mischung und damit etwa 100 mg wirksamer Substanz auf Fumarsäurebasis.For the sake of simplicity, the diluent powder is denoted by VD. If you choose a ratio of recipe M (4): powder VD = 1: 35, then contains a Teaspoon about 5 g of the mixture and thus about 100 mg of active substance based on fumaric acid.

Je nach Bedarf kann man diese Menge nach unten oder oben variieren. Die so hergestellte Zubereitung, sie kann auch in Tablettenform angeboten werden, hat, in Wasser gelöst, einen angenehmen Geschmack. Sie wird auch von Kindern gern eingenommen. Zudem beseitigt sie Magen- und Darmbeschwerden, unter denen Psoriatiker meistens zu leiden haben (Darmdivertikel, Darmentzündungen). Alle Schuppenflechtler sind Bindegewebsschwächlinge. Der Glycinstoffwechsel (9; 10) ist gestört und damit die Aminosäuresequenz des Collagens . Die gesunde Haut enthält nämlich zu 30 % Glycin. In den Schuppen der Psoriatiker fehlt nicht nur Glycin, sondern auch Asparagin-Säure(11). Beide Verbindungen sind via Fumarsäure im Körper leicht synthetisierbar(8).Depending on your needs, you can vary this amount up or down. The preparation produced in this way, it can also be offered in tablet form, has a pleasant taste when dissolved in water. She is also loved by children taken. It also eliminates stomach and intestinal problems, some of which are psoriatic mostly have to suffer (intestinal diverticula, intestinal inflammation). All psoriasis are weak connective tissue. The glycine metabolism (9; 10) is disturbed and therefore the amino acid sequence of collagen. Healthy skin contains 30% glycine. In the dandruff of psoriatic sufferers, not only is glycine missing, but also aspartic acid (11). Both compounds can be easily synthesized in the body via fumaric acid (8).

Nach der von 1959 bis 1973 publizierten Methode zur Behandlung von Psoriasis mit "Fumarsäure" wurden bereits einige Hundert Patienten von Ärzten mit Erfolg behandelt(6; 11) Die neuesten Erkenntnisse jedoch sind Gegenstand dieser Patentschrift. So wurde das Mangansalz (4)des Fumarsäuremonoaethylesters vorteilhaft mit in die Rezepturen genommen, in manchen Fällen auch das Calciumsalz der L(+)Milchsäure miteinbezogen.According to the method published from 1959 to 1973 for the treatment of Psoriasis with "fumaric acid" has already been used by several hundred patients by doctors Success treats (6; 11) The latest findings, however, are the subject of this Patent specification. Thus, the manganese salt (4) of fumaric acid monoethyl ester became advantageous included in the recipes, in some cases also the calcium salt of L (+) lactic acid included.

Auf die enge chemische Beziehung zwischen L(+)Milchsäure und Oxyfumarsäure (Oxalessigsäure) wurde schon 1967 hingewiesen(3) Entgegen der in "Medizin heute" (19) 1970/S 12 (4)vertretenen Ansicht, stellte sich heraus, daß das Mangansalz des Fumarsäuremonoaethylesters keinerlei Beschwerden verursacht. Unverträglichkeit trat nur dann auf, wenn gleichzeitig das entsprechende Cobaltsalz verabreicht wurde. Es hat vielmehr eine ausgezeichnete Wirkungsbreite. Eine wesentliche Bereicherung jedoch stellten die schon eingangs erwähnten Zubereitungen in Gegenwart saurer Salze der Wein-, Zitronen-und Ascorbinsäure dar.On the close chemical relationship between L (+) lactic acid and oxyfumaric acid (Oxaloacetic acid) was mentioned as early as 1967 (3) Contrary to the "Medicine Today" (19) 1970 / S 12 (4), it turned out that the manganese salt of Fumaric acid monoethyl ester does not cause any complaints. Intolerance occurred only if the corresponding cobalt salt was administered at the same time. Rather, it has an excellent range of effects. An essential one However, the preparations mentioned at the outset were enriching in the presence acidic salts of tartaric, citric and ascorbic acid.

Ihre Applikation bewirkt eine schnelle Normalisierung der Stoffwechsellage bei Psoriasis. Sie sind darüber hinaus hervorragende Medikamente bei Durchblutungsstörungen, Altersdiabetes(13)und normalisieren den Cholesterinspiegel sehr schnell. Sie wirken günstig auf den Magen-Darm-Trakt. Das alles ist bei Psoriasis sehr wichtig, denn Psoriasis ist keine Hautkrankheit, sondern eine Stoffwechselentgleisung.Their application causes a rapid normalization of the metabolic situation in psoriasis. They are also excellent medicines for circulatory disorders, Adult-onset diabetes (13) and normalize cholesterol levels very quickly. they seem beneficial to the gastrointestinal tract. All of this is very important in psoriasis because Psoriasis is not a skin disease, but a metabolic imbalance.

Die in den nachfolgenden Beispielen angegebenen Teile sind Gewichtsteile.The parts given in the following examples are parts by weight.

Beispiel 1 Man stelle eine Mischung her aus: 100 Teilen Fumarsäure und 100 Teilen Fumarsäuredimethylester, indem man jede Komponente vorher feinst vermahlt. 2 Teile dieser Mischung verdünnt man mit 50 Teilen Pulver VD und lagert die Zubereitung luft- und wasserdicht in einer Glasflasche.Example 1 Prepare a mixture of: 100 parts of fumaric acid and 100 parts of dimethyl fumarate by fining each component beforehand married. 2 parts of this mixture are diluted with 50 parts powder VD and stored the preparation airtight and watertight in a glass bottle.

/4 bis 1/2 Einnahme pro Tag: 1 Teelöffel vpll in 1 bis 1/2 Glas Wasser vor dem Frühstück. / 4 to 1/2 intake per day: 1 teaspoon vpll in 1 to 1/2 glass of water before breakfast.

Beispiel 2 Man mischt 100 Teile Fumarsäure (feinst gemahlen) 100 Teile Fumarsäuredimethylester (feinst gemahlen) 100 Teile Di-Lithium-Fumarat (feinst gemahlen) 100 Teile Zinksalz des Fumarsäuremonoaethylesters.Example 2 100 parts of fumaric acid (finely ground) are mixed with 100 parts Fumaric acid dimethyl ester (finely ground) 100 parts di-lithium fumarate (finely ground) 100 parts of the zinc salt of fumaric acid monoethyl ester.

3 Teile dieses Gemisches werden mit 50 Teilen Pulver VD vermischt.3 parts of this mixture are mixed with 50 parts of powder VD.

Orale Applikation wie in Beispiel 1 (geeignet für Psoriasis arthropathica).Oral application as in Example 1 (suitable for psoriasis arthropathica).

Beispiel 3 Man mischt 198 Teile Fumarsäure 80 Teile bas. Magnesiumhydroxid-carbonat (Merck) 200 Teile Calciumsalz des Fumarsäuremonoaethylesters 160 Teile Zinksalz des Fumarsäuremonoaethylesters 120 Teile Mangansalz des Fumarsäuremonoaethylesters 2 Teile Kupfersalz des Fumarsäuremonoaethylesters 40 Teile Eisensalz des Fumarsäuremonoaethylesters 200 Teile Fumarsäuredimethylester 1000 Teile.EXAMPLE 3 198 parts of fumaric acid and 80 parts of bas. Magnesium hydroxide carbonate (Merck) 200 parts of calcium salt of fumaric acid monoethyl ester 160 parts of zinc salt of fumaric acid monoethyl ester 120 parts of the manganese salt of fumaric acid monoethyl ester 2 parts of the copper salt of fumaric acid monoethyl ester 40 parts of the iron salt of fumaric acid monoethyl ester 200 parts of dimethyl fumarate, 1000 parts.

3 Teile dieser Rezeptur verdünnt man mit 100 Teilen des eingangs erwähnten Verdünnungspulvers VD. Einen Teelöffel voll davon verrührt man in 1/4 bis 1/2 Glas Wasser und trinkt die Lösung vor dem Frühstück.3 parts of this formulation are diluted with 100 parts of the one mentioned at the beginning Thinner powder VD. Mix a teaspoon full of it in 1/4 to 1/2 glass Water and drink the solution before breakfast.

Beispiel 4 Man stellt die vorher einzeln gemahlenen Komponenten zu folgender Rezeptur zusammen: 208 Teile Zinksalz des Fumarsäuremonoaethylesters 176 Teile Calciumsalz des Fumarsäuremonoaethylesters 80 Teile Lithiumsalz des Fumarsäuremonoaethylesters 40 Teile Eisensalz des Fumarsäuremonoaethylesters 2 Teile Kupfersalz des Fumarsäuremonoaethylesters 80 Teile Mangansalz des Fumarsäuremonoaethylesters 176 Teile Fumarsäuredimethylester 174 Teile Fumarsäure 64 Teile bas. Magnesiumhydroxidcarbonat (Merck) 1000 Teile 50 % des Calciumsalzes können durch das Calciumsalz der L(+)Milchsäure ersetzt werden.Example 4 The components which have previously been individually ground are added the following recipe together: 208 parts of zinc salt of fumaric acid monoethyl ester 176 Parts of calcium salt of fumaric acid monoethyl ester 80 parts of lithium salt of fumaric acid monoethyl ester 40 parts of the iron salt of fumaric acid monoethyl ester, 2 parts of the copper salt of fumaric acid monoethyl ester 80 parts of the manganese salt of fumaric acid monoethyl ester, 176 parts of fumaric acid dimethyl ester 174 parts of fumaric acid 64 parts of bas. Magnesium Hydroxide Carbonate (Merck) 1000 parts 50% of the calcium salt can be replaced by the calcium salt of L (+) lactic acid.

100 - 150 mg der Rezeptur füllt man in dünndarmlösliche uelatine-Kapseln (capsulae operculatae).100 - 150 mg of the formula are filled into uelatine capsules that are soluble in the small intestine (capsulae operculatae).

Applikation: 1 Kapsel pro Tag während des Friihstücks.Application: 1 capsule per day during breakfast.

Vorteilhaft mischt man 4 Teile der Rezeptur mit 100 Teilen des Pulvers VD. Applikation 1 - 2 Teelöffel am Tag in etwas Wasser vor den Mahlzeiten.It is advantageous to mix 4 parts of the formulation with 100 parts of the powder VD. Application 1 - 2 teaspoons a day in a little water before meals.

Beispiel 5 SALBE (externe Behandlung) Man stellt eine Emulsion her aus z. B.Example 5 Ointment (external treatment) An emulsion is prepared from z. B.

14 Teilen DMSO (Infiltrina) (12) 11 Teilen Wasser 3 Teilen Zinksalz des Fumarsäuremonoaethylesters 3 Teilen Fumarsäure 1-2 Tl. Allantoin Diese Emulsion verrührt man gegebenenfalls unter Zusatz von TWEEN 20 bis zur homogenen Konsistenz mit 47 Teilen DDD biolog.14 parts of DMSO (Infiltrina) (12) 11 parts of water 3 parts of zinc salt of the fumaric acid monoethyl ester 3 parts of fumaric acid 1-2 Tl. Allantoin This emulsion If necessary, stir together with the addition of TWEEN 20 until it has a homogeneous consistency with 47 parts DDD biolog.

Hautsalbe (oder einer entsprechenden Salbe Typ W/d auf Kohlenwasserstoffbasis) sowie mit 20 Teilen Vitamin A-Säure-Salbe 0,05 %ig (Hoffmann La Roche).Skin ointment (or a corresponding hydrocarbon-based ointment type W / d) and with 20 parts of vitamin A acid ointment 0.05% (Hoffmann La Roche).

Das Zinksalz des Fumarsäuremonoaethylesters in der Salbe kann auch durch 3 - 4 Teile der Rezeptur aus Beispiel 4 ersetzt werden.The zinc salt of fumaric acid monoethyl ester in the ointment can also can be replaced by 3-4 parts of the formulation from Example 4.

Diese Salben verursachen keine entzündlichen Erytheme(2; 4) und sind trotzdem wirksam. Bei guter Verträglichkeit kann der Vitamin-A-Säure-Salbe-Anteil erhöht werden z. B. auf 34 Teile, oder aber unter 20 Teile gesenkt werden, falls erforderlich. Zweckmäßig reibt man wenig Salbe kräftig in die Haut ein.These ointments do not cause inflammatory erythema (2; 4) and are still effective. If well tolerated, the vitamin A acid ointment can be used be increased z. B. to 34 parts, or below 20 parts, if necessary. It is advisable to rub a little ointment vigorously into the skin.

Beispiel 6 KOPFWASSER Man löst 1 Teil Salicylsäure 1 Teil Fumarsäure 1 Teil Calciumsalz des Fumarsäuremonoaethylesters 0,5 Teile Zinksalz des Fumarsäuremonoaethylesters 0,5 Teile Mangansalz des Fumarsäuremonoaethylesters 0,5 Teile Fumarsäuredimethylester und 0,02 Teile Vitamin A-Säure in 10 Teilen Wasser, 86 Teilen Birkenhaarwasser oder Haarspiritus und in 4 Teilen Glyzerin.Example 6 HEAD WATER Dissolve 1 part of salicylic acid and 1 part of fumaric acid 1 part of calcium salt of fumaric acid monoethyl ester 0.5 part of zinc salt of fumaric acid monoethyl ester 0.5 part of the manganese salt of fumaric acid monoethyl ester, 0.5 part of fumaric acid dimethyl ester and 0.02 part of vitamin A acid in 10 parts of water, 86 parts of birch hair water or Hair alcohol and 4 parts glycerine.

Das Haarwasser wird in bekannter Weise in die Kopfhaut einmassiert.The hair tonic is massaged into the scalp in a known manner.

Beispiel 7 VOLLBAD Man stellt sich eine Mischung her aus: 100 Teilen Fumarsäure (feinst gemahlen) 100 Teilen Fumarsäuredimethylester (feinst gemahlen) 100 Teilen Weinsäure 150 Teilen Kalium- oder Natriumbikarbonat 50 Teilen Zitronensäure 2 - 5 Teelöffel dieser Mischung gibt man in ein Vollbad.Example 7 FULL BATH A mixture is made from: 100 parts Fumaric acid (finely ground) 100 parts of fumaric acid dimethyl ester (finely ground) 100 parts of tartaric acid 150 parts of potassium or sodium bicarbonate 50 parts of citric acid Add 2 - 5 teaspoons of this mixture to a full bath.

Vorher verrührt man in das Bad 2 Esslöffel Praecutan oder SATINA (das Badepulver kann auch tablettiert angewandt werden).Before doing this, stir 2 tablespoons of Praecutan or into the bath SATINA (the bath powder can also be used in tablets).

Ein solches Bad bewirkt eine starke Durchblutung und Rötung der Haut. Zweckmäßig beginnt man mit 2 - 3 Teelöffeln -(7) d.h. mit niedriger Dosierung(7), die man dann später steigert.Such a bath causes a strong blood circulation and reddening of the skin. It is advisable to start with 2 - 3 teaspoons - (7) i.e. with a low dosage (7), which you then increase later.

Claims (2)

PATENTANSPRUCHPATENT CLAIM Leicht dosierbare, wohlschmeckende orale pharmazeutische Zubereitungen zur Behandlung von PSORIASIS, bestehend aus Fumarsäure, ihren neutralen und sauren Salzen, ihren Di-und Mono-Estern, sowie deren Salzen, einschließlich der Mangansalze, dadurch gekennzeichnet, daß man die Fumarsäureverbindungen zweckmäßig in Kombination oder als Einzelkomponenten mit den sauren Alkalisalzen der Wein-, Zitronen- und Ascorbinsäure sowie in Gegenwart von Magnesiumsulfat und Zuckern verdünnt und in Wasser gelöst verabreicht. Easily metered, tasty oral pharmaceutical preparations for the treatment of PSORIASIS, consisting of fumaric acid, its neutral and acidic ones Salts, their di- and mono-esters, and their salts, including the manganese salts, characterized in that the fumaric acid compounds are expediently combined or as individual components with the acidic alkali salts of wine, lemon and Ascorbic acid, as well as in the presence of magnesium sulfate and sugars, diluted and in Dissolved water administered. 2. Pharmazeutische Zubereitungen zur externen Behandlung von PSORIASIS auf Fumarsäurebasis, dadurch gekennzeichnet, daß man die Fumarsäurekomponenten mit sauren Salzen der Wein- und Zitronen- sowie gegebenenfalls mit Vitamin A-Säure zusammen appliziert.2. Pharmaceutical preparations for external treatment of PSORIASIS based on fumaric acid, characterized in that the fumaric acid components with acidic salts of tartaric and lemon and, if necessary, with vitamin A acid together applied.
DE19752530372 1975-07-08 1975-07-08 Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts. Pending DE2530372A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE19752530372 DE2530372A1 (en) 1975-07-08 1975-07-08 Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts.
DE19772703964 DE2703964A1 (en) 1975-07-08 1977-02-01 Preparations contg. fumaric acid, glycine and opt. phosphate - for internal and external treatment of psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19752530372 DE2530372A1 (en) 1975-07-08 1975-07-08 Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts.

Publications (1)

Publication Number Publication Date
DE2530372A1 true DE2530372A1 (en) 1977-01-13

Family

ID=5950938

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19752530372 Pending DE2530372A1 (en) 1975-07-08 1975-07-08 Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts.

Country Status (1)

Country Link
DE (1) DE2530372A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3728188A1 (en) * 1987-08-24 1989-03-09 Pearson & Co Gmbh & Co Fumaric acid esters for the external treatment of psoriasis
EP0312697A2 (en) * 1987-10-19 1989-04-26 Peter Paul Prof. Dr. Speiser Pharmaceutical preparations for treating psoriasis, psoriatic arthritis, neurodermitis and enteritis regionalis Crohn
US4851439A (en) * 1985-01-15 1989-07-25 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5359128A (en) * 1991-01-18 1994-10-25 Izhak Blank Malic acid derivatives and compositions for the treatment of psoriasis
DE19503190A1 (en) * 1995-02-01 1996-08-08 Dietl Hans Means for influencing disorders of bone formation
WO1998052549A2 (en) * 1997-05-20 1998-11-26 Fumapharm Ag Use of fumaric acid derivatives
DE19814358A1 (en) * 1998-03-31 1999-10-07 Fumapharm Ag Use of alkyl hydrogen fumarates for the treatment of psoriasis, psoriatic arthritis, neurodermatitis and enteritis regionalis Crohn
DE19848260A1 (en) * 1998-10-20 2000-05-18 Fumapharm Ag Muri Fumaric acid microtablets
DE19853487A1 (en) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
WO2003087174A2 (en) * 2002-04-18 2003-10-23 Fumapharm Ag Carbocyclic and oxacarbocyclic fumaric acid oligomers
BG64435B1 (en) * 1998-08-31 2005-02-28 Fumapharm Ag The use of fumaric acid derivatives in transplant medicine
US7157423B2 (en) 2001-01-12 2007-01-02 Fumapharm Ag Fumaric acid amides
WO2007006308A1 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
EP1913942A2 (en) 2003-09-09 2008-04-23 Fumapharm AG The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
BG65468B1 (en) * 2000-01-10 2008-09-30 Fumapharm Ag Use of fumaric acid derivatives for treating mitochondrial diseases
US8399514B2 (en) 2007-02-08 2013-03-19 Biogen Idec Ma Inc. Treatment for multiple sclerosis
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US11052062B2 (en) 2004-10-08 2021-07-06 Biogen Swiss Manufacturing Gmbh Controlled release pharmaceutical compositions comprising a fumaric acid ester

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451667A (en) * 1985-01-15 1995-09-19 Speiser; Peter P. Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
US4851439A (en) * 1985-01-15 1989-07-25 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
DE3728188A1 (en) * 1987-08-24 1989-03-09 Pearson & Co Gmbh & Co Fumaric acid esters for the external treatment of psoriasis
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
EP0312697A2 (en) * 1987-10-19 1989-04-26 Peter Paul Prof. Dr. Speiser Pharmaceutical preparations for treating psoriasis, psoriatic arthritis, neurodermitis and enteritis regionalis Crohn
EP0312697A3 (en) * 1987-10-19 1990-04-18 Peter Paul Prof. Dr. Speiser Pharmaceutical preparations for treating psoriasis, psoriatic arthritis, neurodermitis and enteritis regionalis crohn
EP0518388A2 (en) * 1987-10-19 1992-12-16 Peter Paul Prof. Dr. Speiser Pharmaceutical preparations for treating psoriasis, psoriatic arthritis, neurodermitis and enteritis regionalis Crohn
EP0518388A3 (en) * 1987-10-19 1993-03-17 Peter Paul Prof. Dr. Speiser Pharmaceutical preparations for treating psoriasis, psoriatic arthritis, neurodermitis and enteritis regionalis crohn
US5359128A (en) * 1991-01-18 1994-10-25 Izhak Blank Malic acid derivatives and compositions for the treatment of psoriasis
DE19503190A1 (en) * 1995-02-01 1996-08-08 Dietl Hans Means for influencing disorders of bone formation
US5985335A (en) * 1995-02-01 1999-11-16 Orthomol Pharmazeutische Vertriebs Gmbh Agent for acting upon bone formation disturbances containing alkaline citrates, lactates and/or malates
WO1998052549A2 (en) * 1997-05-20 1998-11-26 Fumapharm Ag Use of fumaric acid derivatives
WO1998052549A3 (en) * 1997-05-20 1999-04-08 Fumapharm Ag Use of fumaric acid derivatives
CZ299960B6 (en) * 1997-05-20 2009-01-07 Fumapharm Ag Use of fumaric acid derivative
BG64613B1 (en) * 1997-05-20 2005-09-30 Fumapharm Ag Application of fumaric acid derivatives
DE19814358A1 (en) * 1998-03-31 1999-10-07 Fumapharm Ag Use of alkyl hydrogen fumarates for the treatment of psoriasis, psoriatic arthritis, neurodermatitis and enteritis regionalis Crohn
DE19814358C2 (en) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Use of alkyl hydrogen fumarates for the treatment of psoriasis, psoriatic arthritis, neurodermatitis and enteritis regionalis Crohn
BG64435B1 (en) * 1998-08-31 2005-02-28 Fumapharm Ag The use of fumaric acid derivatives in transplant medicine
BG64836B1 (en) * 1998-10-20 2006-06-30 Fumapharm Ag Fumaric acid microtablets
US6355676B1 (en) 1998-10-20 2002-03-12 Fumapharm Ag Fumaric acid micro tablets
DE19848260A1 (en) * 1998-10-20 2000-05-18 Fumapharm Ag Muri Fumaric acid microtablets
WO2000030622A3 (en) * 1998-11-19 2000-11-02 Fumapharm Ag Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
US7619001B2 (en) 1998-11-19 2009-11-17 Biogen Idec International Gmbh Utilization of dialkylfumarates
US7612110B2 (en) 1998-11-19 2009-11-03 Biogen Idec International Ag Utilization of dialkylfumarates
WO2000030622A2 (en) * 1998-11-19 2000-06-02 Fumapharm Ag Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
US7915310B2 (en) 1998-11-19 2011-03-29 Biogen Idec International Gmbh Utilization of dialkylfumarates
DE19853487A1 (en) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
US8759393B2 (en) 1998-11-19 2014-06-24 Biogen Idec International Gmbh Utilization of dialkylfumarates
US6509376B1 (en) 1998-11-19 2003-01-21 Fumapharm Ag Utilization of dialkyfumarates
US7803840B2 (en) 1998-11-19 2010-09-28 Biogen Idec International Gmbh Utilization of dialkylfumarates
US7320999B2 (en) 1998-11-19 2008-01-22 Fumapharm Ag Dimethyl fumarate for the treatment of multiple sclerosis
US8524773B2 (en) 1998-11-19 2013-09-03 Biogen Idec International Gmbh Utilization of dialkylfumarates
CZ299409B6 (en) * 1998-11-19 2008-07-16 Fumapharm Ag Use of one or more dialkyl fumarates for preparing a pharmaceutical composition and the pharmaceutical composition per se
BG65468B1 (en) * 2000-01-10 2008-09-30 Fumapharm Ag Use of fumaric acid derivatives for treating mitochondrial diseases
US7432240B2 (en) 2001-01-12 2008-10-07 Biogen Idec International Gmbh Fumaric acid amides
US7157423B2 (en) 2001-01-12 2007-01-02 Fumapharm Ag Fumaric acid amides
EP1671965A3 (en) * 2002-04-18 2006-07-26 Fumapharm AG Oxacarbocyclic oligomers of fumaric acid
US7790916B2 (en) 2002-04-18 2010-09-07 Biogen Idec International Gmbh Carbocyclic and oxacarbocyclic fumaric acid oligomers
US7906659B2 (en) 2002-04-18 2011-03-15 Biogen Idec International Gmbh Carbocyclic and oxacarbocyclic fumaric acid oligomers
EP1671965A2 (en) * 2002-04-18 2006-06-21 Fumapharm AG Oxacarbocyclic oligomers of fumaric acid
WO2003087174A3 (en) * 2002-04-18 2004-01-08 Fumapharm Ag Carbocyclic and oxacarbocyclic fumaric acid oligomers
WO2003087174A2 (en) * 2002-04-18 2003-10-23 Fumapharm Ag Carbocyclic and oxacarbocyclic fumaric acid oligomers
EP1913942A2 (en) 2003-09-09 2008-04-23 Fumapharm AG The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
US8980832B2 (en) 2003-09-09 2015-03-17 Biogen Idec International Gmbh Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
US11052062B2 (en) 2004-10-08 2021-07-06 Biogen Swiss Manufacturing Gmbh Controlled release pharmaceutical compositions comprising a fumaric acid ester
US11229619B2 (en) 2004-10-08 2022-01-25 Biogen Swiss Manufacturing Gmbh Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP2186819A1 (en) * 2005-07-07 2010-05-19 Aditech Pharma AG Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
WO2007006308A1 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
US8399514B2 (en) 2007-02-08 2013-03-19 Biogen Idec Ma Inc. Treatment for multiple sclerosis
US11173123B2 (en) 2009-01-09 2021-11-16 Biogen Swiss Manufacturing Gmbh Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix

Similar Documents

Publication Publication Date Title
DE2530372A1 (en) Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts.
DE69233250T2 (en) COMBINATIONS OF CALCIUM AND VITAMIN D
DE69110130T2 (en) ACCESSORIES FROM CALCIUM AND TRACE ELEMENTS.
DE68905096T2 (en) COMPOSITION CONTAINING NIACIN AND GUAR FLOUR.
DE60207877T2 (en) Composition containing procyanidins for reducing appetite in mammals
EP0435913B1 (en) Effervescent tablet
DE60132444T2 (en) TREATING IRRITATION SYNDROME OR DISEASE
EP0326826A1 (en) Medicine with a destructive effect on malignant tumours, process for its manufacture and preparation for use in the therapy of cancer patients
DE3348163C2 (en)
DE1915798C3 (en) Antacid preparation in the form of an aqueous suspension
DE60032509T2 (en) CHROMI-HISTIDINE COMPLEXES AS FOOD ADDITIVES
DE1767017A1 (en) Iron preparation
DE4405545A1 (en) Oral vitamin compsn. with improved resorption
DE68903448T2 (en) PHARMACEUTICAL AND / OR DIETETIC COMPOSITIONS CONTAINING L-CARNITINE AND L-LYSINE.
DE2061370A1 (en) New therapeutic combination
EP0018550B1 (en) Compositions for muscular disease treatment
EP0001124A1 (en) Drug mixtures for improving the utilisation of glucose in the cells and to reduce the bloodsugar level
DE2117762A1 (en) Treatment of alopecia and pharmaceutical preparation for carrying out the treatment
DE2753140C2 (en) Medicines used to treat stomach ulcers
DE2523394A1 (en) PHARMACEUTICAL PREPARATION
DE4201504C1 (en) Oral magnesium preparations, esp. for treatment of cardiac disorders - contain magnesium oxide and further magnesium salt(s), esp. tri:magnesium di:phosphate, as buffer
EP0014821B1 (en) A liquid composition for use in rapid oral cholecystography and process for preparing it
LU501504B1 (en) POWDERED FOOD SUPPLEMENT FOR MAKING A BEVERAGE
DE2429034A1 (en) NUTRITIONAL LIQUID FOR PARENTERAL TRACKING
DE19810383A1 (en) Anti-neoplastic therapy uses of 4-phenyl butyrate or its derivatives,

Legal Events

Date Code Title Description
OHN Withdrawal